• Evolus expanded its partnership with Symatese, securing exclusive rights to commercialize Estyme injectable hyaluronic acid gels in Canada, Australia, New Zealand.
• Launch targeted for 2028, subject to regulatory approvals; adds dermal fillers alongside Nuceiva in those markets.
• Neurotoxin and dermal filler markets in the three countries total about $500 million annually, split 60% neurotoxins, 40% fillers.
• Symatese to handle development, manufacturing, clinical support, regulatory work; Evolus to pay an upfront fee, milestone payments, mid-single-digit royalty.
• Terms include product purchases at a transfer price; deal expected to lift international gross margins using existing commercial infrastructure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evolus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608040830BIZWIRE_USPR_____20260804_BW612699) on August 04, 2026, and is solely responsible for the information contained therein.